CA2300892A1 - Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires - Google Patents

Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires Download PDF

Info

Publication number
CA2300892A1
CA2300892A1 CA002300892A CA2300892A CA2300892A1 CA 2300892 A1 CA2300892 A1 CA 2300892A1 CA 002300892 A CA002300892 A CA 002300892A CA 2300892 A CA2300892 A CA 2300892A CA 2300892 A1 CA2300892 A1 CA 2300892A1
Authority
CA
Canada
Prior art keywords
cpt
administering
camptothecin
alkaline
uptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300892A
Other languages
English (en)
Inventor
Bernard Bouscarel
Kunihiko Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300892A1 publication Critical patent/CA2300892A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des procédés permettant l'administration de composés camptothéciniques tels que l'hydrochlorure d'irinotécane de façon à réduire la diarrhée qui lui est habituellement associée. L'invention concerne également des traitements anticancéreux et anti-SIDA à base de composés camptothéciniques. Ces traitements prévoient l'administration de tels composés camptothéciniques tout en maintenant à un pH alcalin l'intestin et la bile.
CA002300892A 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires Abandoned CA2300892A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8978198P 1998-06-18 1998-06-18
US60/089,781 1998-06-18
PCT/US1999/013906 WO1999065493A1 (fr) 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Publications (1)

Publication Number Publication Date
CA2300892A1 true CA2300892A1 (fr) 1999-12-23

Family

ID=22219554

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300892A Abandoned CA2300892A1 (fr) 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Country Status (7)

Country Link
EP (1) EP1003516A4 (fr)
JP (1) JP2002518332A (fr)
CN (1) CN1325305A (fr)
AU (1) AU764370B2 (fr)
CA (1) CA2300892A1 (fr)
IL (1) IL134592A0 (fr)
WO (1) WO1999065493A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518332A (ja) * 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法
DK1189637T3 (da) 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
CA2295429A1 (fr) * 2000-01-06 2001-07-06 Michael Michael Traitement ou prevention de la diarrhee
AU2002255810A1 (en) * 2001-03-20 2002-10-03 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
EP2087113A2 (fr) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Thérapie de combinaison
WO2016062245A1 (fr) * 2014-10-21 2016-04-28 Johnpro Biotech Inc. Méthodes et formulation pour améliorer la disponibilité orale de cpt-11 tout en réduisant la toxicité gastro-intestinale induite par le cpt-11 dans la thérapie du cancer
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
IE81127B1 (en) * 1989-02-07 2000-03-22 Dimminaco Ag Effervescent composition for oral rehydration
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996011005A2 (fr) * 1994-10-06 1996-04-18 Atlas Leon T Utilisation de camptothecine ou de derives de camptothecine dans la fabrication d'un medicament destine au traitement de maladies virales
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器
JP2002518332A (ja) * 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法

Also Published As

Publication number Publication date
JP2002518332A (ja) 2002-06-25
WO1999065493A1 (fr) 1999-12-23
CN1325305A (zh) 2001-12-05
EP1003516A4 (fr) 2006-07-12
WO1999065493A9 (fr) 2000-03-23
EP1003516A1 (fr) 2000-05-31
AU5083399A (en) 2000-01-05
AU764370B2 (en) 2003-08-14
IL134592A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
US6407117B1 (en) Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US11173209B2 (en) Compositions for drug administration
AU694677B2 (en) Pharmaceutical formulations of highly lipophilic camptothecin derivatives
Kobayashi et al. pH‐dependent uptake of irinotecan and its active metabolite, SN‐38, by intestinal cells
US11413244B2 (en) Liposome composition and pharmaceutical composition
AU671605B2 (en) Combination chemotherapy
Emerson et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
Kehrer et al. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies
CA2300892A1 (fr) Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires
TW450811B (en) Lyophilizate of lipid complex of water insoluble camptothecins
Patankar et al. Nano-particulate drug delivery systems for camptothecins
WO2010025322A2 (fr) Nanodistribution magnétique d'agents thérapeutiques à travers la barrière hémato-encéphalique
JP2003509372A (ja) リン酸エストラムスチンおよびアミノ酸の非経口使用のための処方
US5935967A (en) Pharmaceutical formulations of highly lipophilic camptothecin derivatives
ZA200604757B (en) Pharmaceutical formulations of camptothecins and process for making same
MXPA00001702A (en) Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
Saotome et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma
CN108721214B (zh) 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued